|Description||Adomeglivant has been found to be a glucagon receptor antagonist that could probably be effective for both type-I and type-II diabetes mellitus.|
|Synonyms||Adomeglivant; LY-2409021; Adomeglivant [USAN]; UNII-74Z5ZL2KVG; LY2409021; LY 2409021; 3-[[4-[(1S)-1-[4-(4-tert-butylphenyl)-3,5-dimethylphenoxy]-4,4,4-trifluorobutyl]benzoyl]amino]propanoic acid|
|Storage||Store in a cool and dry place and at 0 - 4 °C for short term (days to weeks) or -20 °C for long term (months to years).|
|Quality Standard||In-house standard|
|Current Developer||Eli Lilly|
LGD-6972 is an orally bioavailable small molecule glucagon receptor antagonist being developed as an adjunct to diet and exercise to improve glycemic control in...
glucagon receptor antagonists-3
glucagon receptor antagonists-3 is a highly potent antagonist of glucagon receptor .
Exenatide acetate is a potent peptide agonist of the glucagon-like peptide 1 (GLP-1) receptor with Ki value of 136 pM. It is a 39 amino acid peptide, which incr...
Ingliforib, with antihyperglycemic and cardioprotective properties, inhibits glycogen phosphorylase.
Exendin (9-39) is a specific and competitive glucagon-like peptide-1receptor antagonist (Kd = 1.7 nM at cloned human GLP-1 receptors). Exendin (9-39) inhibits i...
MK-0893 is a potent, selective glucagon receptor antagonist with high binding affinity with IC(50) of 6.6 nM and functional cAMP activity with IC(50) of 15.7 nM...
BAY-27-9955 is a specific glucagon receptor antagonist.
Adomeglivant has been found to be a glucagon receptor antagonist that could probably be effective for both type-I and type-II diabetes mellitus.
glucagon receptor antagonists-4
glucagon receptor antagonists-4 is a potent glucagon receptor antagonist with great oral bioavailability in vivo.
MK-0893 is a selective glucagon receptor antagonist. It can block glucagon binding to the human GCGR and antagonize glucagon-induced intracellular accumulation ...
Taspoglutide is a long-acting glucagon-like peptide 1 (GLP-1) receptor agonist (EC50= 0.06 nM) under investigation for treatment of type 2 diabetes.
Liraglutide is the long-acting analogue of glucagon-like peptide-1 (GLP-1) receptor which could protect b-cells from apoptosis under conditions associated with ...
Glucagon receptor antagonists 1
Glucagon receptor antagonists-1 is a highly potent glucagon receptor antagonist, which is activated by glucagon and is a member of the class B G-protein coupled...
GRA Ex-25 is an orally active human glucagon receptor antagonist in a transgenic murine pharmacodynamic model, with IC50 of 56 and 55 nM for rat and human gluca...
CP-320626, a carboxamide derivative, is a potent glycogen phosphorylase inhibitor and a possible target for type 2 diabetes therapy. CP-320626 is also a potent ...
glucagon receptor antagonists-2
glucagon receptor antagonists-2 is a highly potent antagonist of glucagon receptor .